Type I IFN Receptor Signaling on B Cells Promotes Antibody Responses to Polysaccharide Antigens
The Journal of Immunology · 15.01.2023 · 210 (2) · 148-157
DOI: 10.4049/jimmunol.2200538 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Immunology, online erschienen am 15.01.2023. Verfasst von M Ariel Spurrier und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology and Immunology, Wake Forest School of Medicine, Winston-Salem, NC. Hauptthemen laut MEDLINE: Antibody Formation, B-Lymphocytes. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, NCI NIH HHS, NCATS NIH HHS.
Abstract (Originalsprache)
We previously reported monophosphoryl lipid A (MPL) and synthetic cord factor trehalose-6,6′-dicorynomycolate (TDCM) significantly increase Ab responses to T cell–independent type 2 Ags (TI-2 Ags) in a manner dependent on B cell–intrinsic TLR4 expression, as well as MyD88 and TRIF proteins. Given the capacity of MPL to drive type I IFN production, we aimed to investigate the extent to which type I IFN receptor (IFNAR) signaling was required for TI-2 responses and adjuvant effects. Using Ifnar1−/− mice and IFNAR1 Ab blockade, we found that IFNAR signaling is required for optimal early B cell activation, expansion, and Ab responses to nonadjuvanted TI-2 Ags, including the pneumococcal vaccine. Further study demonstrated that B cell–intrinsic type I IFN signaling on B cells was essential for normal TI-2 Ab responses. In particular, TI-2 Ag–specific B-1b cell activation and expansion were significantly impaired in Ifnar1−/− mice; moreover, IFNAR1 Ab blockade similarly reduced activation, expansion, and differentiation of IFNAR1-sufficient B-1b cells in Ifnar1−/− recipient mice, indicating that B-1b cell–expressed IFNAR supports TI-2 Ab responses. Consistent with these findings, type I IFN significantly increased the survival of TI-2 Ag–activated B-1b cells ex vivo and promoted plasmablast differentiation. Nonetheless, MPL/TDCM adjuvant effects, which were largely carried out through innate B cells (B-1b and splenic CD23− B cells), were independent of type I IFN signaling. In summary, our study highlights an important role for B-1b cell–expressed IFNAR in promoting responses to nonadjuvanted TI-2 Ags, but it nonetheless demonstrates that adjuvants which support innate B cell responses may bypass this requirement.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Microbiology and Immunology, Wake Forest School of Medicine, Winston-Salem, NC.
ORCID-Profile: M Ariel Spurrier, Karen M Haas
Förderung
- NIAID NIH HHS
- NCI NIH HHS
- NCATS NIH HHS
- HHS | NIH | NIAID | Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases
- HHS | National Institutes of Health
Zitieren
APA
Spurrier, M. A., Jennings-Gee, J. E., & Haas, K. M. (2023). Type I IFN Receptor Signaling on B Cells Promotes Antibody Responses to Polysaccharide Antigens. The Journal of Immunology, 210(2), 148-157. https://doi.org/10.4049/jimmunol.2200538
Vancouver
Spurrier MA, Jennings-Gee JE, Haas KM. Type I IFN Receptor Signaling on B Cells Promotes Antibody Responses to Polysaccharide Antigens. The Journal of Immunology. 2023;210(2):148-157. doi:10.4049/jimmunol.2200538
BibTeX
@article{Spurrier2023,
author = {Spurrier, M Ariel and Jennings-Gee, Jamie E and Haas, Karen M},
title = {Type I IFN Receptor Signaling on B Cells Promotes Antibody Responses to Polysaccharide Antigens},
journal = {The Journal of Immunology},
year = {2023},
volume = {210},
number = {2},
pages = {148--157},
doi = {10.4049/jimmunol.2200538}
}
EUVIMED